The liver is an organ with many indispensable functions in the body. Liver diseases can be caused by numerous ethiological factors, and are divided into two basic groups, according to an anatomical substrate which is primarily affected – on hepatocellular (parenchymal) and billiard diseases. Approximately 10% of patients with liver disease require a surgical procedure (not including a liver transplant) in the last 2 years of life. Because of its reserves and regenerative abilities, the liver can suffer a great deal of damage before the clinical manifestations of its own dysfunction, which is a challenge for the pre-operative assessment of its condition. The goal of preoperative screening is to determine the presence of preexisting liver disease without the need for extensive or invasive testing. Routine testing of liver function has a low prediction value. The post-operative outcome depends on the nature and severity of the existing liver disease, as well as the type of the operation. It is often necessary to treat complications of severe liver damage, such as coagulopathy, thrombocytopenia, ascites, kidney failure, encephalopathy and malnutrition. Predisposition for infections of patients with cirrhosis requires prophilactic use of antibiotics. Induction of anesthesia, bleeding during surgery, hypoxia, hypotension, the use of vasoactive drugs, and even positioning of patients and surgical techniques can reduce intraoperative and perioperative delivery of oxygen in liver and increase the risk of hepatic dysfunction. Pharmacokinetic parameters of anesthetic agents, muscle relaxants, painkillers and sedatives may be altered in connection with plasma proteins, detoxification in liver etc.. The postoperative liver dysfunction depends on surgical trauma, ischemia during surgery or loss of hepatocite mass, and it can be divided into three groups – hepatocelulcular, cholesterol and mixed liver dysfunction. Posthepatectomy liver failure is one of the most serious complications after the liver resection and is a post-operative deterioration of liver capability to maintain its main functions. In recent years, liver function support systems have been developed. Molecular recirculation system with absorption (MARS), modified fractional plasma separations and adsorption (Prometheus) and bioartifical liver and extracorporal device for assistence of liver activity. Extensive clinical studies are needed to prove the effectiveness of these artefical systems for temporary replacement of the edible functions to its recovery or to transplantation.
Ettel MG, Appelman HD. Approach to the Liver Biopsy in the Patient With Chronic Low-Level Aminotransferase Elevations. Arch Pathol Lab Med. 142(10):1186–90.
2.
R M. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol. 21:111–23.
3.
Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology. Mar;59(3):1052-9.
4.
Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 10:117–25.
5.
Pikul J, Sharpe MD, Lowndes R. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation. 57:469–72.
6.
Shirabe K, Matsumata T, Shimada M. A comparison of parenteral hyperalimentation and early enteral feeding regarding systemic immunity after major hepatic resection—the results of a randomized prospective study. Hepatogastroenterology. 44:205–9.
7.
Vernon G, Baranova A, review YZMS. The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34(274).
8.
Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on non-alcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 6(12):1396–402.
9.
Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, et al. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 79(17):4326–30.
10.
European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines. Management of hepatocellular carcinoma J Hepatol. 56:908–43.
11.
Li C, Liang L, Jia HD, Diao YK, Yang T. Letter: Are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Pharmacol Ther. 51(7).
12.
Henderson JM, Anderson CD. The Surgical Treatment of Portal Hypertension. Clin Liver Dis (Hoboken. 15(Suppl 1).
13.
Stone HH. Preoperative and postoperative care. Surg Clin North Am. 57:409–19.
14.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 31(4):864–71.
15.
Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child–Pugh and MELD scores. Clin Gastroenterol Hepatol. 2:719–23.
16.
Capussotti L, Ferrero A, Viganò L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg. 30:992–9.
17.
Christmas AB. Cirrhosis and trauma: a deadly duo. Am Surg. 71:996–1000.
18.
Strunin L. Anesthetic management of patients with liver disease.
19.
Allison SP, Lobo DN. Debate: albumin administration should not be avoided. Crit Care. 4:147–50.
20.
Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int. 26:695–702.
21.
Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 25(2):281–90.
22.
Goldberg DS, French B, Thomasson A, Reddy KR, Halpern SD. Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation. 91(10):1148–52.
23.
Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 28(2):142–52.
24.
Lee WM, RH S, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure. Summary of a workshop Hepatology. 47(4):1401–15.
25.
Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol. 40(2):327–30.
26.
Watkins PB, Seeff LB. Drug-induced liver injury. Summary of a single topic clinical research conference. Hepatology. 43(3):618–31.
27.
Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth. 67(1):84–99.
28.
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. An update Hepatology. 49(4):1335–74.
29.
Cohen JA, Kaplan MM. The SGOT/SGPT ratio–an indicator of alcoholic liver disease. Dig Dis Sci. 24(11):835–8.
30.
Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 25(2):281–90.
31.
Kochanek KD, Xu J, Murphy SL. Preliminary data for 2009. Center for Disease Control and Prevention NCfHS. (16).
32.
Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 26:388–93.
33.
Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 41:553–8.
34.
Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost. 14:1054–66.
35.
Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients. Systematic review World J Gastroenterol. 20:5737–45.
36.
Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J. 4:373–8.
37.
Rosenberg PM, Friedman LS. The liver in circulatory failure. In: Schiff’s Diseases of the Liver. p. 1215–27.
38.
Schenk P, Warszawska J, Fuhrmann V, König F, Madl C, syndrome RKH. Prevalence and predictive value of various cut-offs for arterial oxygenation and their clinical consequences. Wien Klin Wochenschr. 124(17–18):624–32.
39.
Rodríguez-Roisin R, Krowka MJ, Agustí A. Hepatopulmonary Disorders: Gas Exchange and Vascular Manifestations in Chronic Liver Disease. Compr Physiol. 8(2):711–29.
40.
Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 358(22):2378–87.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.